(Post-pandemic Era)-Global Acid Sphingomyelinase Deficiency Drug Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2016-2027
- Report Code : XYZ2438064
- Published On: Apr, 2021
- Category : Medical Devices
- Pages : 107
-
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research published a report for global Acid Sphingomyelinase Deficiency Drug market in this environment.
In terms of revenue, this research report indicated that the global Acid Sphingomyelinase Deficiency Drug market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Acid Sphingomyelinase Deficiency Drug industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Genzyme Corporation aims at producing XX K Units Acid Sphingomyelinase Deficiency Drug in 2020, with XX % production to take place in global market, La Jolla Pharmaceutical Company accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Acid Sphingomyelinase Deficiency Drug Market Include by
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Acid Sphingomyelinase Deficiency Drug Market
Genzyme Corporation
La Jolla Pharmaceutical Company
Merck & Co., Inc.
Okklo Life Sciences BV
Orphazyme ApS
Major Type of Acid Sphingomyelinase Deficiency Drug Covered in Research report:
LJPC-0712
ML-SA1
OKL-1014
Olipudase Alfa
OR-0005
Others
Application Segments Covered in Research Market
Hospital
Clinic
Others
For any other requirements, please feel free to contact us and we will provide you customized report.
-
With tables and figures helping analyze worldwide (Post pandemic Era) Global Acid Sphingomyelinase Deficiency Drug market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Global Acid Sphingomyelinase Deficiency Drug Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope1.1 Product Details and Introduction
1.1.1 LJPC-0712 -Product Introduction and Major Manufacturers
1.1.2 ML-SA1 -Product Introduction and Major Manufacturers
1.1.3 OKL-1014 -Product Introduction and Major Manufacturers
1.1.4 Olipudase Alfa -Product Introduction and Major Manufacturers
1.1.5 OR-0005 -Product Introduction and Major Manufacturers
1.1.6 Others -Product Introduction and Major Manufacturers1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Acid Sphingomyelinase Deficiency Drug Market Assessment, by Segmentation2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis3.1 China Acid Sphingomyelinase Deficiency Drug Market
3.1.1 Top Companies leading Acid Sphingomyelinase Deficiency Drug Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Acid Sphingomyelinase Deficiency Drug Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)3.2 EU Acid Sphingomyelinase Deficiency Drug Market
3.2.1 Top Companies leading Acid Sphingomyelinase Deficiency Drug Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Acid Sphingomyelinase Deficiency Drug Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)3.3 USA Acid Sphingomyelinase Deficiency Drug Market
3.3.1 Top Companies leading Acid Sphingomyelinase Deficiency Drug Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Acid Sphingomyelinase Deficiency Drug Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)3.4 Japan Acid Sphingomyelinase Deficiency Drug Market
3.4.1 Top Companies leading Acid Sphingomyelinase Deficiency Drug Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Acid Sphingomyelinase Deficiency Drug Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)3.5 India Acid Sphingomyelinase Deficiency Drug Market
3.5.1 Top Companies leading Acid Sphingomyelinase Deficiency Drug Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Acid Sphingomyelinase Deficiency Drug Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)3.6 Southeast Asia Acid Sphingomyelinase Deficiency Drug Market
3.6.1 Top Companies leading Acid Sphingomyelinase Deficiency Drug Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Acid Sphingomyelinase Deficiency Drug Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Acid Sphingomyelinase Deficiency Drug Market
3.7.1 Top Companies leading Acid Sphingomyelinase Deficiency Drug Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Acid Sphingomyelinase Deficiency Drug Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)4.1 Acid Sphingomyelinase Deficiency Drug Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream4.2 COVID-19 Impact on Acid Sphingomyelinase Deficiency Drug Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)5.1 Global Acid Sphingomyelinase Deficiency Drug Sales and Growth Rate (2021-2027)
5.2 Global Acid Sphingomyelinase Deficiency Drug Sales Value and Growth Rate (2021-2027)
6 Acid Sphingomyelinase Deficiency Drug Competitive Analysis6.1 Genzyme Corporation
6.1.1 Genzyme Corporation Company Profiles
6.1.2 Genzyme Corporation Product Introduction
6.1.3 Genzyme Corporation Acid Sphingomyelinase Deficiency Drug Production, Revenue (2016-2021)
6.1.4 SWOT Analysis6.2 La Jolla Pharmaceutical Company
6.2.1 La Jolla Pharmaceutical Company Company Profiles
6.2.2 La Jolla Pharmaceutical Company Product Introduction
6.2.3 La Jolla Pharmaceutical Company Acid Sphingomyelinase Deficiency Drug Production, Revenue (2016-2021)
6.2.4 SWOT Analysis6.3 Merck & Co., Inc.
6.3.1 Merck & Co., Inc. Company Profiles
6.3.2 Merck & Co., Inc. Product Introduction
6.3.3 Merck & Co., Inc. Acid Sphingomyelinase Deficiency Drug Production, Revenue (2016-2021)
6.3.4 SWOT Analysis6.4 Okklo Life Sciences BV
6.4.1 Okklo Life Sciences BV Company Profiles
6.4.2 Okklo Life Sciences BV Product Introduction
6.4.3 Okklo Life Sciences BV Acid Sphingomyelinase Deficiency Drug Production, Revenue (2016-2021)
6.4.4 SWOT Analysis6.5 Orphazyme ApS
6.5.1 Orphazyme ApS Company Profiles
6.5.2 Orphazyme ApS Product Introduction
6.5.3 Orphazyme ApS Acid Sphingomyelinase Deficiency Drug Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6
6.6.1 Company Profiles
6.6.2 Product Introduction
6.6.3 Acid Sphingomyelinase Deficiency Drug Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
7 Conclusion
-
The (Post pandemic Era) Global Acid Sphingomyelinase Deficiency Drug Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
New players are entering the (Post pandemic Era) Global Acid Sphingomyelinase Deficiency Drug Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.
Depending upon the type of applications, the (Post pandemic Era) Global Acid Sphingomyelinase Deficiency Drug Market has been segmented into
In 2023, the (Post pandemic Era) Global Acid Sphingomyelinase Deficiency Drug Market share surpassed USD xx million, and between 2024 and 2029, it will grow at a CAGR of yy%.
A handful of disruptive trends, nevertheless, will have a contradictory and significant impact on the development of the (Post pandemic Era) Global Acid Sphingomyelinase Deficiency Drug Market as well as its distribution among its players
The (Post pandemic Era) Global Acid Sphingomyelinase Deficiency Drug Industry stakeholders, executives, and experts, as well as individuals who need to develop consumer-friendly strategies and use technology to stay ahead of the competition.
